Analyst Price Target is $3.10
▲ +232.80% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Pharming Group in the last 3 months. The average price target is $3.10, with a high forecast of $3.10 and a low forecast of $3.10. The average price target represents a 232.80% upside from the last price of $0.93.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Pharming Group.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.